Kate Haviland Blueprint Medicines Corp (BPMC) insider trading activity

Kate Haviland is CHIEF EXECUTIVE OFFICER of Blueprint Medicines Corp. Currently has a direct ownership of 153,177 shares of BPMC, which is worth approximately $14.8 Million. The most recent transaction as insider was on Mar 07, 2024, when has been sold 12,464 shares (Common Stock) at a price of $90.69 per share, resulting in proceeds of $1,130,360. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 153K

0% 3M change

21.92% 12M change

Total Value Held $14.8 Million

Kate Haviland Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 07 2024	SELL Open market or private sale	$1,130,360 $90.69 p/Share	12,464 Reduced 7.52%	153,177 Common Stock
Mar 01 2024	BUY Grant, award, or other acquisition	-	40,000 Added 19.45%	165,641 Common Stock
Mar 06 2023	SELL Open market or private sale	$300,061 $45.19 p/Share	6,640 Reduced 5.02%	125,641 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	40,000 Added 23.22%	132,281 Common Stock
Nov 03 2022	BUY Open market or private purchase	$48,378 $43.98 p/Share	1,100 Added 1.18%	92,281 Common Stock
Mar 07 2022	SELL Open market or private sale	$58,877 $56.18 p/Share	1,048 Reduced 1.14%	91,181 Common Stock
Mar 03 2022	SELL Open market or private sale	$103,604 $60.27 p/Share	1,719 Reduced 1.83%	92,229 Common Stock
Mar 01 2022	BUY Grant, award, or other acquisition	-	40,000 Added 29.86%	93,948 Common Stock
Dec 13 2021	SELL Open market or private sale	$98,130 $98.13 p/Share	1,000 Reduced 1.82%	53,948 Common Stock
Dec 13 2021	BUY Exercise of conversion of derivative security	$36,050 $36.05 p/Share	1,000 Added 1.79%	54,948 Common Stock
Sep 13 2021	SELL Open market or private sale	$99,270 $99.27 p/Share	1,000 Reduced 1.82%	53,948 Common Stock
Sep 13 2021	BUY Exercise of conversion of derivative security	$36,050 $36.05 p/Share	1,000 Added 1.79%	54,948 Common Stock
Jun 28 2021	SELL Open market or private sale	$90,020 $90.02 p/Share	1,000 Reduced 1.82%	53,948 Common Stock
Jun 28 2021	BUY Exercise of conversion of derivative security	$36,050 $36.05 p/Share	1,000 Added 1.79%	54,948 Common Stock
Mar 15 2021	SELL Open market or private sale	$106,460 $106.46 p/Share	1,000 Reduced 1.82%	53,948 Common Stock
Mar 15 2021	BUY Exercise of conversion of derivative security	$36,050 $36.05 p/Share	1,000 Added 1.79%	54,948 Common Stock
Mar 04 2021	SELL Open market or private sale	$171,483 $87.85 p/Share	1,952 Reduced 3.49%	53,948 Common Stock
Mar 01 2021	BUY Grant, award, or other acquisition	-	13,062 Added 18.94%	55,900 Common Stock
Nov 16 2020	SELL Open market or private sale	$41,010 $100.27 p/Share	409 Reduced 0.95%	42,838 Common Stock
Nov 16 2020	BUY Exercise of conversion of derivative security	$14,744 $36.05 p/Share	409 Added 0.94%	43,247 Common Stock
Oct 16 2020	SELL Open market or private sale	$1,354,068 $101.55 p/Share	13,334 Reduced 23.74%	42,838 Common Stock
Oct 16 2020	BUY Exercise of conversion of derivative security	$480,691 $36.05 p/Share	13,334 Added 19.18%	56,172 Common Stock

Also insider at

FULC

Fulcrum Therapeutics, Inc. Healthcare

BCAX

Bicara Therapeutics Inc.

Kate Haviland

CHIEF EXECUTIVE OFFICER

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BPMC shares.

Notify only if

Value

Insider Trading

Get notified when an Blueprint Medicines Corp insider buys or sells BPMC shares.

Notify only if

Operation

Value

Type

News

Receive news related to Blueprint Medicines Corp

Track Activities on BPMC

Account